Xenon sets June 2, 2026 annual shareholder meeting
Xenon Pharmaceuticals Inc. outlined key details for its 2026 annual meeting of shareholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Xenon Pharmaceuticals Inc. outlined key details for its 2026 annual meeting of shareholders. The meeting is scheduled for June 2, 2026, with a record date for notice and voting of April 7, 2026, which is also the beneficial ownership determination date.
Holders of Xenon common shares are entitled to receive notice of and vote at the meeting. The company will not mail materials directly to non-objecting beneficial owners but will pay for distribution to objecting beneficial owners. Xenon is using notice-and-access for both registered and non-registered investors, and the related information was also submitted through a SEDAR+ filing furnished as Exhibit 99.1.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the record date for Xenon Pharmaceuticals (XENE) 2026 annual meeting?
Which securities can vote at Xenon Pharmaceuticals (XENE) 2026 annual meeting?
Is Xenon Pharmaceuticals (XENE) using notice-and-access for its 2026 annual meeting materials?
Will Xenon Pharmaceuticals (XENE) pay for distribution of materials to objecting beneficial owners?
How did Xenon Pharmaceuticals (XENE) communicate its 2026 annual meeting details in Canada?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading |
|
Name of each exchange on which registered |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 |
Other Events |
On March 13, 2026, Xenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2026 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada.
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:
Exhibit Number |
Description |
99.1 |
SEDAR+ filing submitted March 13, 2026. |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
XENON PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
|
|
Date: March 13, 2026 |
|
By: |
/s/ Thomas P. Kelly |
|
|
|
Thomas P. Kelly |
|
|
|
Chief Financial Officer |
|
|
|
|
|
|
March 13, 2026
|
Alberta Securities Commission |
British Columbia Securities Commission |
Ontario Securities Commission |
RE: Xenon Pharmaceuticals Inc.
Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:
|
|
Date of meeting: |
June 2, 2026 |
Record date for notice: |
April 7, 2026 |
Record date for voting: |
April 7, 2026 |
Beneficial ownership determination date: |
April 7, 2026 |
Securities entitled to notice: |
Common Shares |
Securities entitled to vote: |
Common Shares |
Issuer mailing directly to non-objecting beneficial owners: |
No |
Issuer will pay for objecting beneficial owner material distribution: |
Yes |
Issuer using notice-and-access for registered investors: |
Yes |
Issuer using notice-and-access for non-registered investors: |
Yes |
Notice-and-access stratification criteria: |
N/A |
Thank you!
Shelby Behr
Client Success Manager
+1 (919) 410-4412 W
shelby.behr@betanxt.com
Mediant, a BetaNXT business